Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology Guidelines
  • ADA suggests more...

ADA suggests more aggressive lipid, BP and weight targets for diabetes patients in new guideline

Medha BaranwalWritten by Medha Baranwal Published On 2022-12-20T12:15:49+05:30  |  Updated On 2022-12-20T13:36:59+05:30
ADA suggests more aggressive lipid, BP and weight targets for diabetes patients in new guideline

USA: The American Diabetes Association (ADA), in a document published as a supplement in Diabetes Care, has suggested new, more aggressive targets for lipid and blood pressure. New guidelines include updates to recommendations around obesity, hypertension, heart failure medication, social determinants of health, and lipid management.The changes were introduced in the annual ADA Standards...

USA: The American Diabetes Association (ADA), in a document published as a supplement in Diabetes Care, has suggested new, more aggressive targets for lipid and blood pressure. New guidelines include updates to recommendations around obesity, hypertension, heart failure medication, social determinants of health, and lipid management.

The changes were introduced in the annual ADA Standards of Care in Diabetes — 2023, considered the gold standard for the care of more than 100 million Americans with diabetes and prediabetes. The doctors can access the guidelines via an app. 

Now, a blood pressure (BP) target of less than 130/80 mmHg and low-density lipoprotein (LDL) cholesterol targets below 70 mg/dL or no greater than 55 mg/dL is advised for people with diabetes. The targets are dependent on the cardiovascular risk of the individuals. 

Other modifications for 2023 included a new emphasis on weight loss as a goal of therapy for type 2 diabetes; finerenone use in people with diabetes and CKD (chronic kidney disease); guidance for screening and evaluation of peripheral arterial disease for prevention of amputations; guidance on screening for food insecurity; and use of approved point-of-care A1c tests. 

The American College of Cardiology also endorses the cardiovascular disease and risk management section, which has been for the past six years. The new hypertension definition in diabetes patients is ≥ 130 mmHg systolic or ≥ 80 mmHg diastolic BP, repeated on two measurements at different times. Hypertension in patients with established cardiovascular disease can be diagnosed with one measurement of ≥ 180/110 mmHg. It reached safely, and the goal of treatment now is less than 130/80 mmHg. In 2012, the ADA's relaxation of the systolic target to 140 mmHg invited some controversy. 

There are also new lipid targets in the new Standards. For diabetes patients aged 40-75 years at increased cardiovascular (CV) risk, comprising those with one or more atherosclerotic risk factors. To reduce LDL cholesterol by 50% or more from baseline and to a target of less than 70 mg/dL high-intensity, statin therapy is recommended. This is in contrast to the previous target of 100 mg/dL. The document suggests adding a PCSK9 inhibitor or ezetimibe to maximally tolerated statin therapy to achieve that goal. 

For diabetes patients aged 40-75 having established cardiovascular disease, the document recommends high-intensity statin therapy with the target of a 50% or greater reduction from baseline and an LDL cholesterol level of 55 mg/dL or lower. This is in contrast to the previous 70 mg/dL. 

The lower goal than the previous recommendation is based on strong evidence in the literature. A strong recommendation is made for adding a PCSK9 inhibitor or ezetimibe to maximal statins. 

For diabetic people older than 75, the new Standards recommend continuing to take statins for those already on statins. For those who aren't, it may be reasonable to initiate moderate-intensity statin therapy after discussing the benefits and risks.

To access the full guideline, visit https://diabetesjournals.org/care/issue/46/Supplement_1.

Diabetes Care American Diabetes Association type 2 diabetes blood pressure cardiovascular risk Standard of Care in diabetes cardiovascular disease 
Source : Diabetes Care
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok